title: [Lipid management--treatment goal and strategy].
abstract: Diabetic macroangiopathy is known to increase with complicated hyperlipidemia. Large clinical studies indicate that statins are effective in reducing cardiovascular events in subjects with type 2 diabetes. Target goal for LDL cholesterol in type 2 diabetes is less than 100 mg/dl in the United States, whereas it is less than 120mg/dl in Japan. Aggressive lipid-lowering therapy is indicated for type 2 diabetes, especially those with high risk. Other effects than deceasing LDL of statins, i.e. pleiotropic actions, are suggested to contribute to reduction of cardiovascular events. A decrease in HDL cholesterol and an increase in triglycerides are also risk factors for cardiovascular events, but some portion of them are attributed to dyslipidemia associated with insulin resistance.
authors.affiliation: Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation Medical Research Institute Kitano Hospital.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Koshiyama
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000150:complications* / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008019:Life Style; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides